Unresectable Pancreatic Cancer Clinical Trial
Official title:
A Prospective Randomized Trial of Regional Versus Systemic Continuous Gemcitabine Chemotherapy in the Treatment of Unresectable Pancreatic Cancer
Systemic chemotherapy with cytotoxic drug is of limited effectiveness in advanced pancreatic cancer patients. Gemcitabine has been used as the first-line drug for advance pancreatic cancer for over two decades and combinations of gemcitabine with different chemotherapeutic drugs have been investigated to improve the outcomes of pancreatic cancer. However, no substantial improvement in patient survival has been achieved. Locoregional chemotherapy via intra-arterial perfusion or chemoemoblization takes advantage of the increasing local drug concentrations and reducing systemic toxicities. In this study, the investigators hypothesis that artery infusion chemotherapy had a better antitumor effect than systemic chemotherapy. The investigators will analyze and evaluate the effect and safety of an implanted percutaneous left subclavian artery port-catheter drug delivery system for regional chemotherapy of inoperable pancreatic carcinoma.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06026943 -
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer
|
N/A | |
| Not yet recruiting |
NCT02945267 -
Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer
|
Phase 4 | |
| Completed |
NCT01304160 -
Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05251038 -
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03602885 -
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
|
N/A | |
| Completed |
NCT03239184 -
Bioinformation Therapy for Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04002479 -
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT03063554 -
EUS BD vs ERCP TP for Pancreatic Cancer
|
N/A | |
| Completed |
NCT03250273 -
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT06099119 -
Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.
|
Phase 4 | |
| Completed |
NCT02035072 -
Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.
|
Phase 2 | |
| Terminated |
NCT04698915 -
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04789486 -
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03138720 -
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04395469 -
FAZA PET/MRI Pancreas
|
N/A | |
| Recruiting |
NCT04093141 -
Chemotherapy Followed by Irreversible Electroporation in Patients With Unresectable Locally Advanced Pancreatic Cancer
|
N/A | |
| Not yet recruiting |
NCT06278454 -
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)
|
Phase 1 | |
| Terminated |
NCT02166190 -
RFA RCT for Pancreatic or Bile Duct Cancer
|
N/A | |
| Completed |
NCT02282722 -
Improving Informed Consent for Palliative Chemotherapy
|
N/A |